Journal
CURRENT OPINION IN IMMUNOLOGY
Volume 49, Issue -, Pages 37-43Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2017.08.013
Keywords
-
Categories
Funding
- Wellcome Trust [100308/Z/12/Z]
- Danish National Research Foundation [126]
- Medical Research Council [MC_UU_12010/3]
- Oak Foundation [OCAY-15-520]
- Wellcome Trust/Royal Society [204290/Z/16/Z]
- Medical Research Council [MC_UU_12010/3, MC_UU_00008/3] Funding Source: researchfish
- Wellcome Trust [100308/Z/12/Z] Funding Source: researchfish
- MRC [MC_UU_12010/3, MC_UU_00008/3] Funding Source: UKRI
- Wellcome Trust [204290/Z/16/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
Multiple sclerosis (MS) afflicts about 2.5 million people globally and poses a major personal and socioeconomic burden. The recognition of MS as an inflammatory disease, characterized by infiltration of immune cells into the central nervous system, has spurred research into the autoimmune etiology of the condition and has provided the rationale for its treatment through immunomodulation. Experience with immunotherapies in MS to date has suggested a disparity between the observed immune cell infiltration and the progressive loss of neurons. However, recent clinical efforts are providing new insights into progressive MS that once again place the immune system at center stage. This article reviews the main mechanisms of MS immunopathogenesis, and the benefits, risks and challenges of immunomodulatory treatments for the disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available